Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics, Inc. | 2026-05-22 15:05:09 | 3.12 | -0.01 | -0.32 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESPR | 0001434868 | Esperion Therapeutics, Inc. | US29664W1053 | 549300OFU56UKEWVUS92 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 3891 RANCHERO DRIVE, SUITE 150 | ANN ARBOR | MI | 48108 | UNITED STATES | US | 734-887-3903 | 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108 | 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108 | HDL THERAPEUTICS INC | Pharmaceutical | 2008 | Sheldon Koenig | — | http://www.esperion.com/ | 198,200,000 | 259,399,074 | 257,431,942 | Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. | 2026-05-21 17:24:42 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 198,200,000 | -236,900,000 | -54.4473 | 256,810,482 | 58,961,596 | 29.8013 |
| 2024 | 435,100,000 | 292,600,000 | 205.3333 | 197,848,886 | 12,796,181 | 6.9149 |
| 2023 | 142,500,000 | -279,800,000 | -66.2562 | 185,052,705 | 108,479,875 | 141.6689 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| John B. Harlow, Jr. | Chief Commercial Officer | 2025 | 66,875 | 35,000 | 1,608,991 | 0 | 769 | 2,813,103 |
| Sheldon L. Koenig | President, Chief Executive Officer | 2025 | 770,833 | 0 | 1,260,000 | 639,375 | 17,375 | 3,535,512 |
| Benjamin Halladay | Chief Financial Officer | 2025 | 495,833 | 0 | 357,000 | 247,500 | 11,750 | 1,351,935 |
| Benjamin Looker | General Counsel | 2024 | 471,000 | 0 | 205,000 | 213,750 | 11,600 | 1,130,827 |
| Joanne Foody | Chief Medical Officer | 2024 | 388,288 | 0 | 307,500 | 195,200 | 595,860 | 1,870,559 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 294 |
| 2024 | 304 |
| 2023 | 240 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 403,135,000 | 332,314,000 | 116,334,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | 403,135,000 | 332,314,000 | 116,334,000 |
| Research And Development Expenses | 47,852,000 | 46,238,000 | 86,107,000 |
| General And Administrative Expenses | 165,786,000 | 163,073,000 | 142,523,000 |
| Operating Expenses | 342,862,000 | 277,912,000 | 271,897,000 |
| Operating Income | 60,273,000 | 54,402,000 | -155,563,000 |
| Net Income | -22,682,000 | -51,745,000 | -209,248,000 |
| Earnings Per Share Basic | -0.11 | -0.28 | -2.03 |
| Earnings Per Share Diluted | -0.11 | -0.28 | -2.03 |
| Weighted Average Shares Outstanding Basic | 207,865,080 | 187,181,856 | 103,106,616 |
| Weighted Average Shares Outstanding Diluted | 207,865,080 | 187,181,856 | 103,106,616 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 167,852,000 | 144,761,000 | 82,248,000 |
| Marketable Securities Current | — | — | 0 |
| Accounts Receivable | 140,190,000 | 80,142,000 | 48,494,000 |
| Inventories | 105,124,000 | 94,491,000 | 65,623,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 4,496,000 | 18,018,000 | 4,507,000 |
| Total Assets Current | 462,570,000 | 337,998,000 | 201,065,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 338,000 | 254,000 | 0 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 3,316,000 | 5,823,000 | 4,731,000 |
| Total Assets | 465,886,000 | 343,821,000 | 205,796,000 |
| Accounts Payable | 65,068,000 | 51,650,000 | 31,718,000 |
| Deferred Revenue | 34,477,000 | 8,518,000 | 25,402,000 |
| Short Term Debt | 0 | 54,912,000 | — |
| Other Liabilities Current | — | — | 990,000 |
| Total Liabilities Current | 300,810,000 | 246,233,000 | 156,224,000 |
| Long Term Debt | 97,300,000 | 54,600,000 | 261,600,000 |
| Other Liabilities Non Current | 8,739,000 | — | — |
| Total Liabilities Non Current | 467,041,000 | 486,310,000 | 504,566,000 |
| Total Liabilities | 767,851,000 | 732,543,000 | 660,790,000 |
| Common Stock | 245,000 | 196,000 | 118,000 |
| Retained Earnings | -1,623,711,000 | -1,601,029,000 | -1,549,284,000 |
| Accumulated Other Comprehensive Income | 0 | 0 | 0 |
| Total Shareholders Equity | -301,965,000 | -388,722,000 | -454,994,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 105,000 | 63,000 | 164,000 |
| Share Based Compensation Expense | 9,870,000 | 11,993,000 | 11,958,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 60,048,000 | 31,648,000 | 14,765,000 |
| Change In Inventories | 10,633,000 | 28,868,000 | 30,422,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 30,800,000 | 13,904,000 | -6,192,000 |
| Change In Accounts Payable | 20,918,000 | 12,432,000 | 8,678,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -13,093,000 | -23,654,000 | -135,487,000 |
| Purchases Of Marketable Securities | — | 0 | 0 |
| Sales Of Marketable Securities | 0 | 0 | 42,500,000 |
| Acquisition Of Property Plant And Equipment | 0 | 317,000 | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 0 | -317,000 | 42,500,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 72,596,000 | 513,000 | 4,448,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 0 | 99,726,000 | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 244,000 | 29,000 | — |
| Cash From Financing Activities | 36,184,000 | 86,484,000 | 50,460,000 |
| Change In Cash | 23,091,000 | 62,513,000 | -42,527,000 |
| Cash At End Of Period | 167,852,000 | 144,761,000 | 82,248,000 |
| Income Taxes Paid | 612,000 | — | — |
| Interest Paid | 16,266,000 | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.11 | -0.28 | -2.03 |
| Price To Earnings Ratio | -33.6364 | -7.8571 | -1.4729 |
| Earnings Growth Rate | -60.7143 | -86.2069 | -42.3295 |
| Price Earnings To Growth Ratio | 0.554 | 0.0911 | 0.0348 |
| Book Value Per Share | -1.4527 | -2.0767 | -4.4128 |
| Price To Book Ratio | -2.547 | -1.0594 | -0.6776 |
| Ebitda | 62,639,000 | 7,569,000 | -150,108,000 |
| Enterprise Value | 698,548,796 | 376,551,083.2 | 487,640,781.84 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.3222 | -0.2817 | -0.575 |
| Capital Expenditures | 189,000 | 317,000 | 0 |
| Free Cash Flow | -13,282,000 | -23,971,000 | -135,487,000 |
| Return On Equity | 0.0751 | 0.1331 | 0.4599 |
| One Year Beta | 1.1352 | 1.522 | 1.0266 |
| Three Year Beta | 1.1916 | 0.9909 | 0.8532 |
| Five Year Beta | 0.9981 | 0.9894 | 0.961 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer | 2026-03-17 | 6,424 | D | 713,602 |
| Koenig Sheldon L. | Director, President and CEO | 2026-03-17 | 25,578 | D | 2,172,699 |
| Looker Benjamin | Chief Legal Officer | 2026-03-17 | 5,708 | D | 679,348 |
| Halladay Benjamin | Chief Financial Officer | 2026-03-13 | 247,430 | A | 720,026 |
| Halladay Benjamin | Chief Financial Officer | 2026-03-13 | 221,270 | A | 221,270 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 2026-03-31 | 58,636 | 21,400 | 2.74 |
| EverSource Wealth Advisors, LLC | 2026-03-31 | 2,595 | 947 | 2.7402 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2026-03-31 | 35,828 | 13,076 | 2.74 |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 683,342 | 249,395 | 2.74 |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 968,512 | 261,760 | 3.7 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| AQR Funds | 2026-03-31 | Class R6 | QSMRX | 27,023 | 74,043.02 | 0.0444 |
| AQR Funds | 2026-03-31 | Class N | ASMNX | 27,023 | 74,043.02 | 0.0444 |
| AQR Funds | 2026-03-31 | Class I | ASMOX | 27,023 | 74,043.02 | 0.0444 |
| Bridge Builder Trust | 2026-03-31 | Bridge Builder Small/Mid Cap Growth Fund | BBGSX | 15,013 | 41,135.62 | 0.0004 |
| Bridge Builder Trust | 2026-03-31 | Bridge Builder Small/Mid Cap Value Fund | BBVSX | 68,604 | 187,974.96 | 0.0021 |